Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486859/
The pharmacologic management of heart failure with reduced ejection fraction (HFrEF) is well established. Contemporary foundational treatment of HFrEF includes the following 4 standard therapies: (i) a renin-angiotensin system (RAS)...
Conclusion/Relevance: The sodium-glucose cotransporter 2 inhibitors are effective at reducing adverse cardiovascular and renal outcomes in patients with HFrEF and CKD (eGFR ≥ 25 mL/min per 1.73 m2 with dapagliflozin or ≥ 20 mL/min per 1.73 m2 with empagliflozin), although declining kidney function is a risk, due to the osmotic diuretic...
Share
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36143844/
Background and Objectives : Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease. Arterial stiffness is an independent prognostic marker for cardiovascular disease development. We...
Conclusions: Conclusions: SGLT-2 inhibitor treatment with empagliflozin or dapagliflozin in subjects with T2DM failed to improve ambulatory PWV over a mean follow-up of 10 months.
Share
Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control
Source : https://www.sciencedirect.com/science/article/pii/S2049080122012961?via=ihub
Diabetes Mellitus is always associated with both microvascular and macrovascular complications. Cardiovascular and renal complications are the leading cause of morbidity and mortality in these populations. Sodium-glucose co-transporter 2 inhibitors...
Relevance: In this brief review, we outline the potential cardiorenal benefits of these drugs and their future implication to improve glycemic, cardiovascular, and renal outcomes.
Share
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: real world evidence from the Nordic EMPRISE study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36097728/
doi: 10.1111/dom.14870. Online ahead of print. Collaborators, Affiliations 1 Department of clinical science and education Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. 2 Quantify Research, Stockholm, Sweden. 3 Department of Medicine, Huddinge,...
Conclusions: Empagliflozin treatment compared to DPP-4i reduced cardiorenal events and overall mortality, which may explain lower HCRU among empagliflozin users in Sweden.
Share
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36098051/
2022 Sep 13;101161CIRCULATIONAHA122059755. doi: 10.1161/CIRCULATIONAHA.122.059755. Online ahead of print. 1 Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B., T.J.S.). 2 Baylor Scott and White Research Institute, Dallas,...
Conclusions: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction.
Share